The demand for this market will increase as adjuvants will be needed to enhance and extend immune responses while reducing the amount of antigen necessary in each dose. The limited immunogenicity of new and novel vaccine antigens has increased the importance of adjuvant research in vaccine development. There is a need for development of safe and non-toxic adjuvants. Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns.
The Vaccine Adjuvants market can be segmented on the basis of type (Aluminium Salts, Tensoactive Adjuvants, Adjuvant Emulsions, Bacteria derived Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, others), By route of administration (oral, intradermal, intranasal), By mechanism of action (active immunostimulants, carriers, vehicle adjuvants) and By Geography (North America, Europe, APAC & RoW).
Competitive Intelligence analysis in the form of Mergers & Acquisition activity, Collaborations, Agreements, New product launches along with the profiles of major players including Invivogen, Sigma Aldrich, Seppic, Oz Biosciences, Novavax, Adjuvatis, Vaxliant, Adjuvance Technologies, Inc.
Expanding government recommendations for immunizations, technological innovations, Unmet Vaccine market needs for certain diseases, increasing use of recombinant subunit and synthetic vaccines are the driving factors for this market.
Side effects of adjuvants, high toxicity adjuvants, strict regulatory factors, Funding/cost of developing a new adjuvant, lack of scientific awareness of adjuvants are the main restraints.
This Report Offers:
Market Definition for the Global Vaccine Adjuvants Market along with identification of key drivers and restraints for the market.
Market analysis for the Global Vaccine Adjuvants Market, with region specific assessments and competition analysis on a global and regional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the Macro and Micro factors that affect the Global Vaccine Adjuvants market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Report Description
1.2 Markets Covered
1.3 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Market Drivers
3.2.1 Expanding government recommendations for immunizations
3.2.2 technological innovations
3.2.3 Unmet Vaccine market needs for certain diseases
3.2.3 increasing use of recombinant subunit and synthetic vaccines
3.3 Market Restraints
3.3.1 side effects of adjuvants
3.3.2 high toxicity adjuvants
3.3.3 strict regulatory factors
3.3.4 Funding/cost of developing a new adjuvant
3.3.5 lack of scientific awareness of adjuvants
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 By type
5.1.1 Aluminium Salts
5.1.2 Tensoactive Adjuvants
5.1.3 Adjuvant Emulsions
5.1.4 Bacteria derived Adjuvants
5.1.5 Liposome Adjuvants
5.1.6 Carbohydrate Adjuvants
5.2 By route of administration
5.3 By mechanism of action
5.3.1 active immunostimulants
5.3.3 vehicle adjuvants
5.4 By Geography
5.4.1 North America
5.4.3 Asia Pacific
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to new market players
7. Company Profiles
7.2 Sigma aldrich
7.4 Oz Biosciences
7.8 Adjuvance Technologies, Inc